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To better define the efficacy and tolerability of the new anticonvulsant topiramate in pediatric patients, the clinical courses of
49 children with intractable seizures were monitored during topiramate therapy. The 80% of children who had complex partial
seizures experienced better seizure control with topiramate than the 20% who had generalized seizures. Efficacy was greatest
with doses between 2.5 and 7.5 mg/kg/day. More than half the children on topiramate experienced adverse effects which could
interfere with learning at school, but 20% demonstrated increased alertness or improved behavior. Topiramate is effective and
may be considered as part of the treatment pathway for complex partial seizures in children, although careful monitoring of
cognitive function is required.
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Topiramate (TPM) is a new antiepileptic drug that
acts through blocking of sodium channels, enhanc-
ing GABA-induced influx of chloride, and inhibit-
ing kainate/AMPA glutamate receptors1. Although the
usefulness of TPM has been clearly demonstrated in
adults, less information is available concerning the ef-
ficacy and tolerability of TPM in children. We reviewed
the clinical course of all patients with intractable
seizures in our university-based Pediatric Neurology
Clinic, who were started on TPM after the drug was
approved for use in the USA.
Materials and methods
The effects of TPM were studied in all children who
were started on TPM between February 1997 and
September 1997. Patients were divided into two groups
based on seizure type: children with complex par-
tial epilepsy and children with generalized epilepsy.
Medical records were reviewed at 1, 3 and 6 months
following start of therapy for seizure type, seizure fre-
quency, side effects, TPM dose and concurrent medi-
cation. A scale of measuring improvement in seizuresPreliminary work was presented in abstract from at the Annual
Meeting of the American Epilepsy Society (Boston, MA, USA,
7–10 December 1997), which appears in Epilepsia 38 (Suppl. 8):
193–194.
1059–1311/99/010038 + 03 $12.00/0was adopted: 4 represented a 100% reduction in seizure
frequency, 3 represented a <75% reduction, 2 repre-
sented a >50% improvement, 1 represented a <50%
improvement, 0 represented no change, and −1 repre-
sented an increase in seizure frequency.
Results
A total of 49 children were studied, including 23
boys and 26 girls, who ranged in age from 1.5 to 19
years (mean 9.8 years). Children with complex par-
tial epilepsy constituted 80% of the group, and patients
with generalized epilepsy constituted 20%. Three pa-
tients with Lennox–Gastaut syndrome were included
in the group with generalized epilepsy. Most children,
whether they had partial or generalized seizures, had
received five or six antiepileptic drugs before being
started on TPM. Of the 49 patients, 13 received TPM
as monotherapy and 36 received TPM as adjunctive
therapy. At the end of 1 month, 44 patients remained
on TPM. The number of patients available for review
at 3 months was 41, and at 6 months was 34. This
decrease was caused by patients who were started on
TPM later and received medication for less than 3 or 6
months, as well as by patients who were taken off TPM
for inefficacy or adverse effects.
In our study TPM proved more effective in control-
ling partial seizures than in controlling generalized
seizures (Table 1). Furthermore, among patients with
generalized seizures, TPM appeared more effectivec© 1999 British Epilepsy Association
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Table 1: Efficacy by seizure type: seizure improvement scale
(−1 to C4).
1 month 3 months 6 months
Complex partial
seizures 1:5 .n D 36/ 2:2 .n D 34/ 2:0 .n D 28/
Generalized
seizures 1:8 .n D 8/ 1:0 .n D 7/ 1:0 .n D 6/
Table 2: Efficacy of multiple AEDs: seizure improvement
scale (−1 to C4).
1 month 3 months 6 months
Gabapentin 3:0 .n D 2/ 4:0 .n D 2/ 4:0 .n D 1/
Carbamazepine 2:6 .n D 5/ 2:2 .n D 5/ 2:4 .n D 5/
Felbamate 0:8 .n D 4/ 3:0 .n D 3/ 2:3 .n D 3/
Valproate 1:6 .n D 9/ 1:7 .n D 9/ 2:0 .n D 7/
Lamotrigine −0:3 .n D 4/ 2:0 .n D 4/ 1:5 .n D 2/
TPM alone 1:7 .n D 13/ 2:0 .n D 11/ 1:2 .n D 9/
Table 3: Efficacy and dose: seizure improvement scale (−1 to
C4).
1 month 3 months 6 months
<2:5mg=kg=d 1:7 .n D 3/ 2:3 .n D 3/ 1:3 .n D 3/
2:5− 5:0 mg=kg=d 2:2 .n D 9/ 2:3 .n D 9/ 2:8 .n D 8/
5:0− 7:5 mg=kg=d 1:3 .n D 12/ 2:6 .n D 10/ 2:1 .n D 7/
7:5− 10 mg=kg=d 1:8 .n D 6/ 2:2 .n D 6/ 1:0 .n D 6/
>10 mg=kg=d 0:5 .n D 4/ 1:0 .n D 4/ 0:5 .n D 4/
Table 4: Adverse effects of topiramate.
Number of Percent of
patients patients
Decreased appetite 14 28
Decreased cognition 11 22
Decreased speech 8 16
Decreased energy 7 16
Worsened behavior 7 14
Increased sleepiness 7 14
Increased appetite 4 8
New-onset drooling 3 6
Decreased sleep 3 6
Table 5: Beneficial effects of topiramate.
Number of Percent of
patients patients
Increased alertness 8 16
Improved behavior 4 8in controlling seizures at 1 month than at 6 months.
Among patients with complex partial epilepsy, we re-
viewed the efficacy of TPM as monotherapy and as ad-
junctive therapy. Findings are summarized in Table 2,
with drugs listed in order of decreasing efficacy at 6
months. While results suggest that the combination of
TPM with gabapentin, carbamazepine, or felbamate is
particularly effective, the numbers are small and not
clinically significant.
TPM doses were escalated at a rate of 25 to 50 mg
per week. To determine if there were variations in effi-
cacy because of dose, we evaluated efficacy as a func-
tion of dose among the 34 children with complex par-
tial epilepsy. Results indicate that efficacy was greatest
with doses between 2.5 and 7.5 mg/kg/day (Table 3). At
lower doses, between 2.5 and 5.0 mg/kg/day, efficacy
appeared to increase over time, while at higher doses,
between 7.5 and 10.0 mg/kg/day, efficacy appeared to
decrease over time.Adverse effects reported during treatment with TPM
were monitored (Table 4). Although decreased appetite
was the most commonly reported single effect, a con-
stellation of effects reflecting increased psychomotor
dysfunction were far more significant. Of the 49 pa-






Beneficial effects were reported in some patients (Ta-
ble 5). Of the 49 patients, 20% reported improvement
in one or both of the following:
 increased alertness,
 improved behavior.
Among these 10 children, the mean seizure improve-
ment scores were 1.3, 1.4, and 1.4 at 1, 3 and 6 months,
respectively. Among patients in the entire cohort, 31%
reported beneficial effects or no adverse effects.
Discussion
Topiramate is a monosaccharide derivative of the nat-
urally occurring d-fructose with a sulfamate sub-
stitution. It is thought to have a broad range of
antiepileptic activity that functions primarily to pre-
vent seizure spread rather than raise seizure thresh-
old. Its three postulated mechanisms include modu-
lating voltage-dependent sodium conductance, poten-
tiating inhibitory GABA-evoked currents, and block-
ing the kainate/AMPA subtype of the excitatory gluta-
mate receptor. TPM also inhibits some carbonic anhy-
drase isoenzymes; however, its effect is generally much
weaker than that of acetazolamide.
Findings in our study indicate that TPM is an ef-
fective anticonvulsant medication in children, particu-
larly for those with intractable complex partial seizures.
Among the children with partial seizures who were re-
viewed after 3 months and after 6 months, half expe-
rienced a greater than 50% reduction in seizure fre-
quency. The response among the children with gen-
eralized seizures was less encouraging. Our findings
are concordant with those from a single-center open-
label trial of TPM monotherapy substitution in five pe-
diatric patients with complex partial epilepsy, which
40 E. C. Moreland et al.
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daily dosages. Neurology 1996; 46: 1684–1690.emphasized that TPM monotherapy may be effec-
tive if dose titrations of TPM and the concomitant
antiepileptic drug are undertaken carefully2. Our find-
ings, however, are somewhat different than those from a
multi-center open-label study of adjunctive TPM ther-
apy in 18 children with Lennox–Gastaut syndrome, in
which 75% of patients reported a greater than 50%
decrease in the total number of seizures2. The results
of two large, double-blind, placebo-controlled trials of
adjunctive TPM therapy in children with refractory
partial-onset seizures and with Lennox–Gastaut syn-
drome are pending2.
The minimal effective dose of TPM as adjunctive
therapy is approximately 200 mg/day3. In two recent
multi-center adult studies of adjunctive TPM therapy,
maximal seizure reduction rates were seen in patients
taking between 400 and 1000 mg/day of TPM4, 5. In
our study, maximal efficacy was seen at doses between
2.5 and 7.5 mg/kg/day. Also, efficacy at the lower range
of these doses (2.5 to 5.0 mg/kg/day) was observed to
remain steady and, in several cases, increase over time.
In our study, a significant percentage of adverse ef-
fects attributed to TPM were CNS-related. These in-
cluded decreased cognition, somnolence, decreased
speech, and worsened behavior. Over half of the pa-
tients in our study experienced one or more of these
side effects, any of which could adversely affect learn-
ing at a critical age. However, because adverse effects
that could interfere with learning may be subtle and
develop insidiously, the use of objective measures to
monitor changes in cognition may be beneficial. While
there is evidence that many of the CNS-related side ef-
fects may dissipate or disappear completely over time1,
we did not continue patients on TPM for the duration
of the study if they experienced unacceptable adverse
effects. It is important to note that TPM does not uni-formly produce adverse CNS effects. Twenty percent
of children in our study experienced increased alertness
and/or improved behavior. Finally, decreased appetite
with subsequent weight loss was a common adverse
effect in our study, affecting 28% of patients. This is
consistent with other findings that weight loss may be
one of the more common effects3, 4.
We conclude that TPM is significantly effective in
improving seizure control in children and may be con-
sidered as part of the treatment pathway for those
with complex partial seizures. Although several new
antiepileptic drugs have been introduced in this decade,
none have proven to be entirely safe or effective. While
further studies continue, TPM at present may be the
safest and most effective new drug in the treatment of
pediatric epilepsy. However, careful monitoring of cog-
nitive function will be required in pediatric patients.
